Recombinant Activated Factor VII (rFVIIa) in the Management of Major Obstetric Haemorrhage: A Case Series and a Proposed Guideline for Use
Major obstetric haemorrhage remains a significant cause of maternal morbidity and mortality. Previous case reports suggest the potential benefit of recombinant activated factor VII (rFVIIa: NovoSevenR) as a haemostatic agent. We performed a retrospective review of the use of rVIIa in major obstetri...
Saved in:
Main Authors: | Charlotte Bomken, Sue Mathai, Tina Biss, Andrew Loughney, John Hanley |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2009-01-01
|
Series: | Obstetrics and Gynecology International |
Online Access: | http://dx.doi.org/10.1155/2009/364843 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Late diagnosed factor VII deficiency – a rare but significant haemorrhagic diathesis
by: Karolina Małgorzata Różycka, et al.
Published: (2024-12-01) -
Maternal Deaths due to Obstetric Haemorrhage in Dodoma Regional Referral Hospital, Tanzania
by: Mzee M. Nassoro, et al.
Published: (2020-01-01) -
Failure of Recombinant Activated Factor VII in Treatment of Diffuse Alveolar Hemorrhage due to Cryoglobulinemic Vasculitis
by: Dania Khoulani, et al.
Published: (2014-01-01) -
An Intranasal Vaccination with a Recombinant Outer Membrane Protein H against Haemorrhagic Septicemia in Swamp Buffaloes
by: Anucha Muenthaisong, et al.
Published: (2020-01-01) -
Clinical Practice Guidelines for Subarachnoid Haemorrhage Treatment
by: José Ramón Tejera del Valle, et al.
Published: (2009-03-01)